MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
7 December 2021
Join us in celebrating Professor Georgina Long AO, winner of the 2021 NSW Premier's Award for Wildfire Highly Cited Publication.
The 2021 NSW Premier's Wildfire Highly Cited Publication Award is presented to an individual or research team for a highly cited publication that has a significant impact on the cancer field.
This year, the publication is: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (Lancet Oncol. 2018 May;19(5):672–to681).
The report was authored by Professor Georgina Long AO together with MIA's Professor Richard Scolyer AO, Associate Professor Alexander Menzies, Maria Gonzalez and Jarem Edwards.
Originally published in 2018, it has now been cited an incredible 427 times around the world – showing its vital role in improving outcomes for people with advanced melanoma.
“This trial single-handedly changed practice overnight,” Professor Long explains.
The MIA team’s research aimed to establish the efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with metastatic melanoma that had spread to the brain (active melanoma brain metastases).
“Our ABC trial (Anti-PD1 Brain Collaboration) was conducted across Australia, and it showed that combination immunotherapy significantly improved the long-term durable control of melanoma in patients with brain metastases,” Professor Long says.
“It is the only randomised trial demonstrating that combination was so effective, and has much higher response and survival than single agent anti-PD1 immunotherapy.”
This is a significant conclusion, as this treatment may lead to better outcomes for people with advanced melanoma, as well as other cancers.
Professor Long leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma and is a previous recipient of the Cancer Institute NSW Outstanding Cancer Researcher Award.
“Our advances and successes in melanoma research are a true team effort,” Professor Long reflects. “This is only possible through the collaborative work of the many talented and dedicated researchers who are part of the MIA team in conjunction with our world class trials centre.”
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.